Trials in Esophageal Ca, HCC Fall Short MedPage Today In a separate GiCS presentation, results from a phase III trial also were disappointing for everolimus (Afinitor) in hepatocellular carcinoma that had progressed during or after treatment with sorafenib (Nexavar). Cetuximab Plus Chemoradiation. For the ... |
